Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients Without a Timely Response to Their Short-acting Opioids

Next Previous
Trial Profile

An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients Without a Timely Response to Their Short-acting Opioids

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 06 Mar 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use

Most Recent Events

  • 29 Feb 2016 Status changed from recruiting to withdrawn prior to enrolment as per the ClinicalTrials.gov record.
  • 14 Oct 2014 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017, as reported by Clinicaltrials.gov record,
  • 14 Oct 2014 Status changed from not yet recruiting to recruiting, as reported by Clinicaltrials.gov record,

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top